You are here

DEVELOPMENT OF AN IMAGING MARKER FOR PARKINSON'S DISEASE

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43NS043826-01
Agency Tracking Number: NS043826
Amount: $99,755.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2002
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
MOLECULAR NEUROIMAGING, LLC 60 TEMPLE ST, STE 8A
NEW HAVEN, CT 06510
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 DANNA JENNINGS
 (203) 401-4300
 DJENNINGS@MNIMAGING.COM
Business Contact
 JACK MARIOTTI
Phone: (203) 401-4300
Email: JMARIOTTI@MNIMAGING.COM
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant): The development of disease modifying agents in Parkinson's disease has rapidly expanded the need for in vivo markers
for diagnosis and monitoring disease progression. Dopamine transporter (DAT)
imaging offers the promise of an objective measure of dopaminergic degeneration
allowing for identification of changes in the brain that occur early in the
illness, prior to clinical diagnosis. The primary goal of this project is to
examine the sensitivity and specificity of DAT imaging using (3-CIT and SPECT
imaging as a diagnostic marker in subjects with suspected PD or PS.
Neurologists will identify subjects in whom they have genuine uncertainty
regarding diagnosis of PD or PS. The neurologists will be asked to document
their 'best guess' diagnosis on a Diagnostic Accuracy Questionnaire at the time
of referral. Subjects with suspected PD or PS will be evaluated clinically and
with DAT imaging at MNI. The blinded Parkinson's expert will re-examine the
subject in 6 months and make a final clinical diagnosis, which will serve as
the gold standard diagnosis for each subject. The DAT imaging diagnosis will
be compared to the 'gold standard' clinical diagnosis to determine the
sensitivity of (3-CIT and SPECT imaging as a diagnostic marker in PD and PS.
This project is a crucial step to begin to establish B-CIT and SPECT imaging as
an objective diagnostic biomarker prior to definitive diagnosis.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government